Pfizer to buy Biohaven for $11.6B: 4 things to know

Pfizer has agreed to acquire the migraine treatment maker Biohaven Pharmaceuticals for $11.6 billion, the drugmaker said May 10.

Read the full post at Becker's Hospital Review - Healthcare News